explore -WSS

explore

author：hotspot 2025-09-03 11:52:53 - browse：984

Photograph of an abandoned lab with empty bottle, boxes, and beakers all around. -- biotech coverage from STAT — Adobe

SAN DIEGO — It was spring 2020, and Histogen, a small biotech with big ambitions to regenerate tissues throughout the body and turn a profit in the process, had just gone public. The company’s leadership believed they were poised for success — until everything slowly and irreversibly fell apart.

Three years later, Histogen no longer develops therapies. It has abandoned efforts to reverse baldness, replenish cartilage in achy knees, and quell infection and inflammation.

The company has no lab. It has no headquarters. It has just two employees, including a chief financial officer who also serves as secretary, CEO, and president. Histogen’s stock trades below $1 a share. And even that is coming to a close. On Thursday, the Nasdaq suspended trading of Histogen shares after determining that the company’s operations and assets are negligible, meaning the biotech is now officially a shell of its former self.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Apple is now the first public company to be valued at $3 trillion
Next article： No plane should take off without an EpiPen onboard

WSS

Adults seen as increasingly susceptible to measles

Amazon expands telehealth clinic nationwide

Scientists inch closer to single

Physician groups backed by private equity giant lobby on mergers

Vertex non

What the airline industry can learn from medicine

hotspot

explore

hotspot

Tori Bowie and the unacceptable rates of Black maternal death

Megan Rapinoe shares emotional post following US Women's World Cup exit

Virginia high school admissions case could be legal follow

Wildfire pollution widens asthma inequities on Long Island

Heart attack and stroke risk calculators need revising

The high personal cost of affirmative action for Black doctors

Anesthesiologist group: stop taking Ozempic before surgery

Hyundai and Kia recall nearly 92,000 vehicles and tell owners to park them outside due to fire risk

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Illinois Supreme Court finds assault weapons ban constitutional

entertainment

Physician groups backed by private equity giant lobby on mergers

What the US credit downgrade means for the economy, your finances

Novo Nordisk touts Wegovy study, but still struggling with supply

Amazon expands telehealth clinic nationwide

Listen: Biogen's situation, Wegovy's risks, & biotech insider trading

Surge in Apellis stock fueled by confidence in safety of its eye drug

explore

hotspot

knowledge

focus